KNSA
Price:
$21.28
Market Cap:
$1.54B
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin cond...[Read more]
Industry
Biotechnology
IPO Date
2018-05-25
Stock Exchange
NASDAQ
Ticker
KNSA
According to Kiniksa Pharmaceuticals, Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.45B. This represents a change of 9.47% compared to the average of 1.32B of the last 4 quarters.
The mean historical Enterprise Value of Kiniksa Pharmaceuticals, Ltd. over the last ten years is 746.38M. The current 1.45B Enterprise Value has changed 19.32% with respect to the historical average. Over the past ten years (40 quarters), KNSA's Enterprise Value was at its highest in in the September 2024 quarter at 1.71B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.
Average
746.38M
Median
638.65M
Minimum
522.68M
Maximum
1.13B
Discovering the peaks and valleys of Kiniksa Pharmaceuticals, Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 78.08%
Maximum Annual Enterprise Value = 1.13B
Minimum Annual Increase = -29.93%
Minimum Annual Enterprise Value = 522.68M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.13B | 22.83% |
2022 | 922.55M | 33.56% |
2021 | 690.73M | -29.93% |
2020 | 985.71M | 78.08% |
2019 | 553.51M | 5.90% |
2018 | 522.68M | -10.89% |
2017 | 586.58M | 1.81% |
The current Enterprise Value of Kiniksa Pharmaceuticals, Ltd. (KNSA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
915.47M
5-year avg
857.13M
10-year avg
746.38M
Kiniksa Pharmaceuticals, Ltd.’s Enterprise Value is less than Nuvalent, Inc. (6.38B), greater than Ventyx Biosciences, Inc. (80.09M), less than Arcellx, Inc. (4.79B), greater than Cullinan Oncology, Inc. (630.54M), greater than Day One Biopharmaceuticals, Inc. (963.46M), less than Structure Therapeutics Inc. (1.75B), less than Karuna Therapeutics, Inc. (12.43B), greater than Phathom Pharmaceuticals, Inc. (480.38M), greater than Replimune Group, Inc. (984.10M), greater than Nuvectis Pharma, Inc. (81.37M), greater than Lyra Therapeutics, Inc. (23.90M), greater than Kronos Bio, Inc. (5.32M), greater than Gossamer Bio, Inc. (331.04M), greater than Cogent Biosciences, Inc. (929.30M), greater than Larimar Therapeutics, Inc. (363.34M), greater than Kura Oncology, Inc. (807.00M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Spero Therapeutics, Inc. (-8426888.00), greater than Bolt Biotherapeutics, Inc. (30.96M), greater than Coherus BioSciences, Inc. (259.52M), less than Gracell Biotechnologies Inc. (5.61B), greater than Neoleukin Therapeutics, Inc. (-6333315.00),
Company | Enterprise Value | Market cap |
---|---|---|
6.38B | $6.75B | |
80.09M | $130.81M | |
4.79B | $4.89B | |
630.54M | $730.17M | |
963.46M | $1.38B | |
1.75B | $1.91B | |
12.43B | $12.60B | |
480.38M | $638.64M | |
984.10M | $1.02B | |
81.37M | $98.54M | |
23.90M | $12.37M | |
5.32M | $54.49M | |
331.04M | $157.63M | |
929.30M | $1.01B | |
363.34M | $393.05M | |
807.00M | $839.85M | |
8.24B | $8.19B | |
-8426888.00 | $63.24M | |
30.96M | $22.14M | |
259.52M | $125.58M | |
5.61B | $989.87M | |
-6333315.00 | $8.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kiniksa Pharmaceuticals, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kiniksa Pharmaceuticals, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Kiniksa Pharmaceuticals, Ltd.'s Enterprise Value?
What is the highest Enterprise Value for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the 3-year average Enterprise Value for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the 5-year average Enterprise Value for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
How does the current Enterprise Value for Kiniksa Pharmaceuticals, Ltd. (KNSA) compare to its historical average?